MediClin AG

  • WKN: 659510
  • ISIN: DE0006595101
  • Land: Deutschland

Nachricht vom 04.05.2020 | 12:51

MediClin AG: Free bed capacity led to a decline in sales and earnings in the first quarter of 2020 - no reliable forecast for the 2020 financial year yet possible

DGAP-News: MediClin AG / Key word(s): Quarter Results
04.05.2020 / 12:51
The issuer is solely responsible for the content of this announcement.

Offenburg, May 2020

Free bed capacity led to a decline in sales and earnings in the first quarter of 2020 - no reliable forecast for the 2020 financial year yet possible

In the first quarter of 2020, Group sales of the MEDICLIN Aktiengesellschaft (MEDICLIN) of EUR 167.4 million was at the level of the same quarter of 2019. Sales in the post-acute segment fell by EUR 2.9 million, or 2.8%. The acute segment improved its sales by EUR 3.2 million, or 5.4%. Sales in the nursing care business area were slightly below the previous year's level.

Group-EBIT of EUR -3.9 million (Q1 2019: EUR 1.6 million) is reported for the first quarter of 2020. In the post-acute segment, segment earnings amounted to EUR -2.2 million (Q1 2020: EUR 2.9 million) and in the acute segment EUR -0.3 million (Q1 2019: EUR -0.5 million). .

In the first three months of 2019, EUR 9.5 million (gross) were invested (Q1 2019: EUR 11.2 million), mainly in the reconstruction or expansion of the clinics and in the medical equipment. As of March 31, 2020, cash and cash equivalents amounted to EUR 28.5 million (31.12.2019: EUR 37.2 million).

Free capacity created in the fight against the Corona virus

A lower capacity utilization in the clinics had a negative impact on earnings for both the Group and the segments compared to the same quarter of the previous year. Due to the spreading of the coronavirus pandemic, MEDICLIN's acute clinics have cancelled all non-essential operations since mid-March 2020 and have increased ventilaton capacites by 40 %. The post-acute clinics, in turn, have kept bed capacities free for coronavirus patients or to ease the burden on the regional hospitals at more than half of the facilities as agreed with the respective Land governments.

Return to normal not expected before the second half of 2020

At present, it is not yet foreseeable to what extent the protective shield set up by the government will effectively compensate for the financial burdens actually incurred due to declining occupancy rates at the hospitals. This will show in the months to come. Given the current situation, the Management Board does not assume at present that the expectations published for the 2020 financial year will be reached. As soon as the development can be reliably estimated, the Management Board will issue a new forecast for the current financial year.

Presently, MEDICLIN assumes that the situation will not return to normal before the second half of the year. Then a certain catch-up effect or respectively an increase in the demand for medical and therapeutic services may occur.

The interim report as of March 31, 2020 is available on the homepage of MEDICLIN in German and English from today on.


About MEDICLIN AG (Ticker: MED; WKN: 659 510)

MEDICLIN owns 36 clinics, seven nursing care facilities and nine medical care centres. The Group has about 8,500 beds/places and a headcount of about 10,500. With its strong network, MEDICLIN can offer its patients integrated care from the first visit to the doctor to surgery, post-operative rehabilitation and follow-up care at home. Doc-tors, therapists and nurses work together closely to achieve the best results. MEDICLIN plans the care of persons in need in accordance with their individual requirements and personal needs.

MEDICLIN - A company of the Asklepios Group.

04.05.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this


Solutiance: Hohe Wachstumsdynamik durch den Ausbau des Plattformgeschäfts erwartet

Im ersten Halbjahr 2020 konnte Solutiance den eingeschlagenen Wachstumskurs fortsetzen und im Rahmen dessen die Gesamtleistung (Umsatz zzgl. Bestandsveränderungen) um rund 75 % auf 0,66 Mio. € (1. HJ 2019: 0,38 Mio. €) erhöhen. Das Unternehmen erwartet für das Gesamtjahr durch den weiteren Ausbau der softwarebasierten Dienstleistungen einen Umsatzsprung im Vergleich zum Vorjahr auf rund 3 Mio. €. Bei einem von uns ermittelten Kursziel von 4,85 € vergeben wir das Rating KAUFEN.

Aktuelle Research-Studie


Original-Research: SBF AG (von Montega AG): Kaufen

23. September 2020